TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Biofarma teams up with Novo Nordisk for locally produced insulin
The new Bio Farma-Novo Nordisk partnership aims to improve both availability and access by locally producing insulin as an affordable treatment in the country's battle against increasing diabetes prevalence.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Danish pharmaceutical firm Novo Nordisk Indonesia and state-owned pharma company Bio Farma inked an agreement to collaborate on diabetes drug production in Indonesia on July 10, 2024. (Bio Farma)
State-owned pharmaceutical company Bio Farma has inked a partnership agreement with Novo Nordisk to produce insulin in Indonesia.
The Danish pharmaceutical company is behind the diabetes treatment drug Ozempic, which has gained popularity in its alternative use as a weight loss drug.
Under the partnership, Bio Farma is responsible for manufacturing the medicine while Novo Nordisk is to contribute its expertise in diabetes care and insulin production.
Bio Farma president director Shadiq Akasya said the partnership would improve access to affordable, quality diabetes treatment and raise awareness about the importance of managing chronic diabetes.
"Achieving these goals requires a joint commitment, especially from the government, to support the production of innovative domestic products," Shadiq said in a statement on Wednesday.
Read also: Civil groups renew call for sugary drinks tax
Diabetes mellitus, more commonly known as diabetes, was the third leading cause of death in 2019 in Indonesia among all chronic diseases at 57.42 deaths per 100,000 population, CNBC Indonesia reported, citing data from the Institute for Health Metrics and Evaluation.
